About
BioTerm Pharmaceuticals develops therapeutics for the prevention of preterm labor and for the induction of labor. The company has developed the patent-pending Preventerm molecule for the prevention of preterm labor and the patented Inducterm molecule for labor induction. Preventerm is designed to block three of the five factors that prepare the cervix for labor, representing an effective multistep inhibition of the enzymes that begin the labor process. By attacking metalloproteinases and cytokine precursors, Preventerm interrupts several steps in the biological pathway, thereby preventing labor for up to a week, with 90% efficacy. Inducterm works by the reverse process, providing collagenase to begin the breakdown of cervical proteins and thereby inducing labor in three to five hours. Both of the companys drugs are based on scientifically and clinically proven molecules that are safe, inexpensive, and easily administered with minimal side effects. BioTerm Pharmaceuticals is currently seeking an equity investment to broaden management and to enhance marketing and business development activities in the U.S. and Europe.
Q&A
- What is BioTerm Pharmaceuticals' primary focus?
- BioTerm Pharmaceuticals develops therapeutics for the prevention of preterm labor and for the induction of labor.
- What is the status of BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals is currently inactive, having ceased to operate in July 2019.
- When was BioTerm Pharmaceuticals founded?
- BioTerm Pharmaceuticals was founded in January 2002.
- What is the employee count for BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals has an employee count in the 1-10 range.
- What is the name of BioTerm Pharmaceuticals' lead molecule for preventing preterm labor?
- BioTerm Pharmaceuticals has developed the patent-pending Preventerm molecule for the prevention of preterm labor.
- What is the name of BioTerm Pharmaceuticals' lead molecule for labor induction?
- BioTerm Pharmaceuticals has developed the patented Inducterm molecule for labor induction.
- Who is a key member of BioTerm Pharmaceuticals' team?
- Israel Shamir Lebovitz is the President, Chief Medical Officer, and Founder of BioTerm Pharmaceuticals.
- What is BioTerm Pharmaceuticals' current funding stage?
- BioTerm Pharmaceuticals is currently in the Pre-Funding stage.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Former names | S.I. Biotechnology |
|---|---|
| Founded | 2002-1 |
| Employees (exact) | 6 |
| Status reason | Non Active, Jul 2019 ceased to operate |